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Summary
Objectives—The administration of empiric systemic anticoagulation (ESA) before confirmatory
radiographic testing in patients with suspected pulmonary embolism (PE) may improve outcomes,
but no data have been published regarding current practice. We describe the use of ESA in a large
prospective cohort of emergency department (ED) patients and report the outcomes of those
treated with ESA compared with patients not receiving ESA.
Methods—12-center, noninterventional study of ED patients who presented with symptoms
concerning for PE. Clinical data including pretest probability and decision to start ESA were
recorded at point of care by attending physicians. Patients were followed for adverse in-hospital
outcomes and recurrence of venous thromboembolism.
Results—ESA was initiated 342/7932 (4.3%) of enrolled patients, including 142/618 (23%)
patients with high pretest probability. Patients receiving ESA had more abnormal vital signs and
were more likely to have a history of venous thromboembolism than those who did not receive
ESA. Overall, 481/7,932 (6.1%) had PE diagnosed, 72/481 (15.0%) with PE had ESA, and 72/342
(21%) of ESA patients had PE. Three patients (0.9%, 95%CI: 0.2–2.5%) who received ESA
suffered hemorrhagic complications compared with 38 patients (0.5%, 95%CI: 0.4–0.7%) who did
not receive ESA.
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Conclusions—In this multicenter sample, ED physicians administered ESA to a small,
generally more acutely ill subset of patients with high pretest probability of PE, and very few had
hemorrhagic complications. ESA was not associated with any clear difference in outcomes. More
study is needed to clarify the risk versus benefit of ESA.
Keywords
Pulmonary embolism; empiric anticoagulation; decision-making; venous thromboembolism
Introduction
Delay in the initiation of anticoagulation for patients with diagnosed pulmonary embolism
(PE) has been associated with higher rates of venous thromboembolism (VTE) recurrence
and worsened patient outcomes including disability and death.1–6 In an urban teaching
hospital with 24 hours per day, 7 days per week imaging capability, Kline et al found the
median time duration between patient presentation and administration of heparin was 8
hours for patients who had PE diagnosed in the ED versus 33 hours for patients with delayed
diagnosis.5 Prior work has proposed that the benefit of empiric systemic anticoagulation
(ESA, i.e., the administration of heparin prior to knowing the results of confirmatory
diagnostic testing) outweighs the risk in patients who engender a high pretest probability for
PE.7 However, to our knowledge, no prior investigation has examined the current practice
patterns and associated patient outcomes for ESA in a cohort of patients with suspected PE.
This study examines a large cohort of patients presenting to 12 EDs with symptoms
concerning for PE using methodology specifically designed to examine the frequency of
ESA use and patient outcomes. We hypothesized that ESA would be reserved
disproportionately for a subset of severely ill patients with high pretest probability of PE and
that the use of ESA would be associated with a low incidence of hemorrhagic complications.
Methods
Study Design and Setting
This was a secondary analysis of a prospective cohort of patients presenting to 12 EDs who
were evaluated for PE.8 Study sites included 10 academic centers and 2 community
hospitals in the United States. Patients were enrolled from July 1, 2003 through November
30, 2006. The study protocol was approved by the Institutional Review Boards of each
participating hospital.
Study Population
For a patient to be eligible for enrollment, a physician was required to have sufficient
suspicion for PE to order objective diagnostic testing in the ED. This included D-dimer
measurement, CT pulmonary angiography, ventilation/perfusion (VQ) scanning or venous
ultrasonography. We specifically required that this testing be performed with the intent of
evaluating for acute PE and excluded patients who underwent testing solely for suspected
deep venous thrombosis (DVT) or other conditions.
Study centers had the option of enrolling patients during randomly selected 8 hour periods
or consecutively with a goal of enrollment of >85% of eligible subjects. To ensure
compliance with the 85% goal, centers underwent quarterly audits of all D-dimer testing,
VQ scans and CT pulmonary angiograms obtained during enrollment periods via
retrospective review of ordering databases.
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Measurements
Data were entered at the point of care by ED physicians into a web-based, secure, electronic
data collection form. This protocol specified that the form be completed before the results of
confirmatory diagnostic testing for PE were known. A full description of the content and
methodology for this data collection system has been published.9 Explicit definitions were
provided for each data field. Automated checks were employed to prevent upload of missing
or nonsensical data. Forms could be initiated at any time after a test was ordered for PE, and
the form could be edited for up to 24 hours after upload. The primary predictor for this
analysis was administration of ESA. The field used to determine ESA status was the seventh
out of 74 questions, immediately after a set of questions used to estimate the Wells score and
the physician's unstructured (gestalt) estimate of the pretest probability of PE.10;11 The ESA
field required the clinician to state whether or not anticoagulation (heparin or low molecular
weight heparin) was given prior to the performance of diagnostic imaging for VTE.
Physicians were also asked to document the presence of absence of contraindications to
anticoagulation with heparin. Absolute contraindications included any history of intracranial
or intraocular hemorrhage; ischemic stroke within the previous 3 months; presence of a
cerebral vascular malformation or intracranial metastasis; suspected aortic dissection;
history of heparin induced thrombocytopenia; known bleeding diathesis; and uncontrolled
hemorrhage. Relative contraindications included: uncontrolled hypertension (systolic blood
pressure greater than 180mmHg and/or diastolic blood pressure greater than 110 mmHg);
intracranial pathology not constituting an absolute contraindication; major surgery within
the preceding 3 months; internal bleeding within the previous 4 weeks; active peptic ulcer
disease; non-compressible vascular punctures; and allergy to heparin. Clinicians who
completed these forms received standardized instruction, administered by a full-time study
coordinator who traveled to each site to initiate the study. We performed quality assurance
testing on a convenience audit of 1022 uploaded forms compared against the medical record
and found 98% agreement between the answer coded in the ESA field and any
anticoagulation orders on the medical record.9 The dose, route and type of anticoagulation
were not specifically recorded.
The diagnosis of PE in this study required either a CT angiogram or conventional pulmonary
angiogram demonstrating a pulmonary arterial filling defect interpreted as positive for acute
PE, a high probability VQ scan, or autopsy positive for PE. Imaging studies were interpreted
by board certified radiologists not affiliated with the study. Patients were followed in
hospital for hemorrhagic complications, ICU admission and death, and to 45 days for
recurrence of PE or DVT. The data collection form allowed the hemorrhage site to be
determined as 1. Intracranial, 2. Gastrointestinal, 3. Puncture site, or 4. Other. .All sites
underwent an initiation visit from the study monitor that included a verbal and written
explanation of how follow-up variables were defined. A bleeding event was recorded as
present if the event caused a clinically significant change in care, including stopping or
reversal of anticoagulation, or a transfusion, or surgical or endoscopic intervention
Data Analysis
Patients were grouped by presence or absence of ESA and presence or absence of PE at the
time of initial presentation. Two × 2 contingency tables containing frequencies of adverse
outcomes among each group were constructed.
Continuous data are described as mean ± standard deviation (SD) or median (intraquartile
range [IQR] as appropriate. Categorical data are presented as percentages along with the
95% confidence interval (CI) when appropriate (Clopper-Pearson method). Multivariate
logistic regression was performed using demographic information and a set of 15 additional
characteristics (listed in Table 2) hypothesized to have an effect on clinicians' decision to
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administer ESA. Post-hoc power calculation was performed to determine the study's ability
to detect both a difference in the rate of hemorrhagic complications and a difference in the
rate of VTE recurrence. Using the entire cohort of patients (regardless of presence or
absence of PE), and setting α=0.05 and β=0.20, the study was able to detect a 1.5%
difference in the rate of hemorrhagic complications in those administered ESA compared
with those not receiving ESA. Among patients initially diagnosed with PE, the study was
powered to detect a difference in VTE recurrence of 9% between those receiving ESA and
those who did not. Statistical analyses were performed using StatsDirect v. 2.6.2
(StatsDirect, Cheshire, England).
Results
We enrolled 7,932 patients with necessary data to assess use of ESA and determine
outcomes in accordance with the protocol. A total of 342 patients (4.3%) received
anticoagulation prior to any confirmatory diagnostic testing. Ninety-one (26%) of these
patients received low molecular weight heparin and the others received unfractionated
heparin. We did not record dosing information. Table 2 compares the characteristics of all
patients based upon use or non-use of ESA. Multivariate regression revealed that patients
given ESA were older, more likely to be male, have a personal or family history of VTE,
and have a higher heart rate, respiratory rate, and Wells score, and a lower oxygen saturation
and systolic blood pressure. Curiously, the frequency of relative or absolute
contraindications to anticoagulation were not significantly different between patients who
received ESA (22 of 342 or 6.4%) versus patients not receiving ESA (418 of 7590 or 5.5%,
95% CI for difference of 0.9%: −1.2% to 4.1%).
From the initial cohort of 7,932 patients, 481 (6.1%) were diagnosed with PE at the time of
initial presentation. 72 (21.1%) of the 342 patients receiving ESA were diagnosed with PE.
Therefore, 15.0% of the patients diagnosed with PE received anticoagulation prior to
imaging, and 85.0% patients with PE were not administered ESA. Patients receiving pretest
anticoagulation were significantly more likely to be diagnosed with PE (OR: 4.68, 95%CI:
3.49–6.22). 11 patients who received ESA and were not diagnosed with PE were eventually
diagnosed with DVT.
Table 1 displays the proportion of patients belonging to each of the four possible therapeutic
and diagnostic outcome groups (ESA+/PE+, ESA−/PE+, ESA+/PE−, ESA−/PE−) among
those grouped as high (Wells score >6, or physician gestalt-estimated pretest probability
>40%), medium (Wells Score 2–6, or estimated pretest probability 15–40%) or low pretest
probability (Wells score <2, or estimated pretest probability <15%). 22.2% of patients with
Wells score >6 received ESA, compared with 23.0% of patients with high gestalt estimate
probability (95%CI for difference: −5.7%–6.9%). Among the 618 patients that had a high
pretest probability based on Wells score or physician gestalt, 74 (12%) had an absolute or
relative contraindication to anticoagulation and 425 (69%) were admitted to the hospital.
Subsequently, we compared the outcomes of patients receiving ESA to those not receiving
early anticoagulation. Table 3 shows the frequency of significant patient outcomes grouped
by the use of ESA and presence or absence of PE. Regardless of the presence of absence of
PE, patients receiving ESA were significantly more likely to be admitted to an intensive care
unit (12.6% vs. 2.8%, 95%CI for difference: 6.7%–13.7%). The in-hospital mortality of
ESA patients was also higher in the cohort as a whole (3.2% vs. 1.0%, 95%CI for
difference: 0.8%–4.7%). VTE recurrence within 45 days was noted in 5/72 (6.9%) of PE+
patients who received ESA and 16/409 (3.9%) of PE+ patients who did not receive ESA.
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The incidence of in-hospital hemorrhagic complications was low. Among the cohort as a
whole, 3/342 patients (0.9%) receiving ESA suffered a hemorrhagic complication compared
with 38/7590 (0.5%) who did not receive ESA (95% CI for difference: −0.2%–2.1%). One
of the three given ESA was diagnosed with PE and had puncture site bleeding. Of the two
patients who received ESA, but were not subsequently diagnosed with PE, one of these
patients was diagnosed with DVT and had gastrointestinal bleeding, while the other patient
had no PE or DVT but had an a non-fatal bleeding complication specified as “other
bleeding” which did not require admission to an intensive care unit. None of the three
patients who had ESA and bleeding had a transfusion or required endoscopy or surgery for
hemorrhage control.
Of the 38 without ESA, two had intracranial hemorrhage, 16 had gastrointestinal
hemorrhage, eight had puncture site bleeding and 12 had bleeding at other sites. Two of the
38 received systemic fibrinolytic treatment and two others intrapulmonary fibrinolytic prior
to their bleeding episode. Eleven of these 38 received a blood transfusion and five had
endoscopy, but none underwent surgery to control hemorrhage.
Discussion
The authors provide this set of data to provide additional information about the patterns of
use and patient outcomes associated empiric systemic anticoagulation for suspected
pulmonary embolism. We believe this topic is important, because the clinical question of the
risk and benefit of ESA often arises in the emergency department and in medical
malpractice lawsuits. The previous literature examining the use of ESA for suspected VTE
prior to imaging is quite limited. Prior outcome studies have been restricted to patients with
confirmed VTE.1–6 Moreover, no previous studies has specifically examined the outcomes
of patients based upon administration of systemic anticoagulation prior to confirmatory
imaging. To our knowledge, this is the first study to examine the characteristics of a cohort
patients with suspected PE who received ESA and to compare the outcomes of patients with
and without ESA stratified by ultimate diagnosis of PE. This comparison is important
because in our sample, 79% (72/342) of patients who receive ESA ultimately were found to
not have PE. Thus, help determine whether ESA is harmful or helpful, it is important to
measure outcomes of patients with suspected PE and who received ESA, but ultimately had
no PE after diagnostic testing.
Our results indicate that emergency physicians administer ESA to fewer than 25% of
patients with a high pretest probability for PE, regardless if obtained by Wells score or
clinician gestalt. Patients receiving ESA engendered the perception of higher acuity, as
evidenced by the higher rate of ICU admission. Patients receiving ESA who were not
diagnosed with PE also had higher mortality rates. We interpret the vital sign and
comorbidity data in Table 2 as evidence that this increase in mortality was secondary to the
increased severity of the clinical presentation and underlying illness of patients who
received ESA. Another important observation was the very low overall rate of significant
hemorrhagic complications associated with ESA; indeed, less than 1% of patients (2/270)
who received ESA--but ultimately had no PE--also suffered a bleeding complication.
Strengths of the present study include the large sample size and the number of centers, both
academic and community, which participated in data collection. Treatment decisions for
patients in this study were made at the discretion of the individual physicians, who could
rely on their own gestalt, available clinical decision rules or any combination of these.
However, a lack of data regarding the dose, route and type of heparin used is a limitation of
this study. Furthermore, there are no data pertaining to the time elapsed between initiation of
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treatment and the completion of confirmatory testing. Finally, as patients were not
randomized, one cannot conclude a causal effect of ESA on patient outcomes.
Our data show no clear evidence of benefit or harm from the use of ESA in current practice.
We believe these data allow two preliminary inferences: 1. That ED physicians currently
reserve ESA for very sick patients, which precludes the use of a noninterventional (“wild
type”) study to answer the question of whether ESA is harmful or helpful, and 2. The rate of
hemorrhagic complications was low in patients administered ESA despite their high acuity
of illness. We conclude that a randomized trial to test the impact of ESA on mortality in
patients with moderate to high pretest probability for PE is warranted.
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Table 2
Patient characteristics by pretest treatment group
Characteristic ESA n=342 No ESA n=7590 P Value*
Age (years) 54.5 ± 16.7 48.7 ± 17.3 0.001
Female (%) 195 (57) 5130 (68) 0.001
White (%) 208 (61) 4327 (57) 0.14
Black (%) 107 (31) 2695 (36) 0.12
Hispanic (%) 24 (7) 458 (6) 0.08
Asian (%) 2 (1) 72 (1) 0.32
Highest HR (beats/min) 101.2 ± 24.8 91.8 ± 20.8 <0.001
Highest RR (breaths/min) 23.3 ± 5.8 20.7 ± 4.8 <0.001
Lowest SBP (mm Hg) 126.0 ± 25.7 131.2 ± 23.8 0.02
Lowest SaO2 (%) 94.3 ± 5.5 96.6±3.7 <0.001
Wells Score 3.5 (1.5–6) 1.5 (0–3) <0.001
Prior VTE (%) 87 (25) 770 (10) <0.001
Family History of VTE (%) 46 (13) 774 (10) 0.007
Malignancy † (%) 41 (12) 448 (6) 0.06
Immobility (%) 58 (17) 705 (9) 0.11
Exogenous Estrogen Use (%) 27 (8) 634 (8) 0.10
Recent Surgery (%) 28 (8) 492 (6) 0.61
History of CHF (%) 42 (12) 539 (7) 0.30
History of CAD (%) 48 (14) 785 (10) 0.85
History of COPD (%) 61 (18) 795 (10) 0.96
Any End-Stage Condition (%) 13 (4) 146 (2) 0.76
Data are displayed as mean ± SD (or median (IQR) for Wells score) for continuous data and n (%) for dichotomous characteristics. Abbreviations:
HR: heart rate, RR: respiratory rate, SBP: systolic blood pressure, SaO2, room air oxygen saturation, VTE: venous thromboembolism, CHF:
congestive heart failure, CAD: coronary artery disease, COPD: chronic obstructive pulmonary disease. Immobility was defined as any condition
which resulted in limited mobility of the patient, e.g. bed-bound or paralyzed patients, or a limb, e.g. use of a cast or external fixator, for a period of
greater than 48 hours. End-stage condition was defined as any ailment resulting in a life expectancy of less than 6 months.
† Currently treated or metastatic malignancy
*
From multivariate logistic regression
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